Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Sunday, November 13, 2016

Alemtuzumab Better than Interferon in Multiple Sclerosis -


                                                                  
  

Click here to receive MS news via e-mail


Alemtuzumab provided more benefits to patients with relapsing remitting multiple sclerosis (RRMS) who had poor response to other therapies than subcutaneous interferon-B-1a (SC IFN-B-1a) provided, according to the results of a recent study. Conducted by Gavin Giovannoni, MD, PhD, of Queen Mary University of London, and colleagues, the study was published in the journal Neurology on October 12, 2016.   





The authors begin by discussing the fact that limiting disability is an important part of caring for patients with MS, but that interest is increasing in not only limiting disability but in helping patients with disability improve. They say, “Interest is growing in aiming for confirmed disability improvement (CDI), a higher standard for therapeutic efficacy than merely slowing disability accumulation.” In pursuit of that goal, the researchers say the aim of the present study was “to characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing remitting multiple sclerosis with inadequate response to prior therapy.” 

- See more 









MS Views and News
Providing educational information, resources and services for those affected by MS





No comments: